Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations
June 23, 2023 16:30 ET
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc....
INVESTOR ALERT: Kaplan Fox Investigates Mersana Therapeutics, Inc. (Nasdaq: MRSN)
June 19, 2023 18:54 ET
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc....
Mersana Therapeutics Announces Appointment of Brian C. DeSchuytner as Senior Vice President of Finance and Product Strategy
June 12, 2019 08:00 ET
|
Mersana Therapeutics, Inc.
Brings Significant Strategic and Operational Experience from Leading Oncology Companies Company Announces Chief Financial Officer Transition CAMBRIDGE, Mass., June 12, 2019 (GLOBE...
Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer
November 27, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates
November 13, 2018 07:00 ET
|
Mersana Therapeutics, Inc.
XMT-1536 Phase 1 Dose Escalation Ongoing with Data Expected in the First Half of 2019 XMT-1522 Phase 1 Dose Escalation Enrollment Resumed Mersana to Present New Data on Dolasynthen and...
Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer
November 12, 2018 09:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Scientists Present Updates on XMT-1522, XMT-1536 and the Dolaflexin Platform at World ADC 2018
November 12, 2018 07:00 ET
|
Mersana Therapeutics, Inc.
Mersana Chief Scientific Officer, Timothy B. Lowinger, Ph.D. to chair 2018 Conference CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage...
Mersana Announces FDA Lifts Partial Clinical Hold for XMT-1522
September 17, 2018 07:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present at Upcoming Investor Conferences
August 30, 2018 16:01 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Announces Second Quarter 2018 Financial Results and Provides Business Updates
August 14, 2018 16:20 ET
|
Mersana Therapeutics, Inc.
Response to the FDA Partial Clinical Hold Submitted This Week Strong Balance Sheet with a cash position of $97M to close Q2 CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Mersana...